What targeted therapies are available for Non-Small Cell Lung Cancer

Targeted Therapies for Non-Small Cell Lung Cancer

Targeted therapies are an important treatment option for NSCLC patients whose cancers have specific genetic mutations or alterations. These drugs work differently than traditional chemotherapy—they target the specific proteins that help cancer cells grow.

How Targeted Therapy Works

According to the NCCN Guidelines for Patients, targeted therapy works by stopping proteins called kinases that help cancer cells divide and grow. Think of it like turning off the "growth switch" that's stuck in the "on" position in cancer cells.

Key Genetic Mutations That Guide Treatment

The NCCN Clinical Practice Guidelines strongly recommend that all patients with advanced or metastatic NSCLC receive broad molecular profiling—comprehensive genetic testing to identify actionable mutations. This testing should look for:

• EGFR mutations (most common)
• ALK rearrangements
• KRAS mutations
• ROS1 fusions
• BRAF mutations
• NTRK fusions
• MET exon 14 skipping
• RET alterations
• HER2 (ERBB2) alterations

Types of Targeted Therapies Available

1. Kinase Inhibitors (Oral Pills)

These are taken at home as pills and block specific proteins that drive cancer growth:

• Used for EGFR mutations, ALK rearrangements, ROS1 fusions, BRAF mutations, and other driver mutations
• Examples include osimertinib (for EGFR), alectinib (for ALK), and entrectinib (for ROS1 and NTRK)

2. Antibody Therapies (IV Infusions)

These are given through a vein and work by attaching to receptors on cancer cells to block growth signals:

• Target specific receptors like EGFR and MET
• Include VEGF antibodies (like bevacizumab) that stop blood vessel growth to tumors

3. Antibody-Drug Conjugates

These combine two drugs in one medicine—an antibody that finds cancer cells plus a drug that attacks them. Given by infusion.

Important Testing Considerations

According to the NCCN Guidelines, molecular testing can be done through:

• Tissue biopsy (from the tumor)
• Plasma (blood) testing (liquid biopsy)
• Combination of both (which can speed up getting results)

If one test is negative, a complementary method may be used to confirm results.

Clinical Decision-Making Framework

The NCCN Guidelines explain that doctors consider:

1. Whether a driver mutation is found - This determines if targeted therapy is an option
2. Timing of results - If urgent treatment is needed, doctors may start chemotherapy while waiting for molecular test results, then switch to targeted therapy once results are available
3. Your overall health - Whether you can tolerate the specific therapy
4. Previous treatments - What you've already received affects future options

Questions to Ask Your Oncology Team

Since targeted therapy selection depends on YOUR specific genetic test results, ask your doctor:

1. "What genetic mutations or alterations were found in my tumor?"
2. "Based on my specific mutations, which targeted therapies are options for me?"
3. "What are the benefits and side effects of each targeted therapy option?"
4. "Are there any clinical trials available for my specific mutation?"
5. "If I start with chemotherapy first, when can we switch to targeted therapy once my results are back?"

Important Reminder

Your oncologist will determine the most appropriate targeted therapy approach based on your complete clinical picture—including your specific genetic test results, overall health, and treatment history. The availability of molecular testing before treatment is associated with longer overall survival in patients with advanced NSCLC, so getting tested is an important first step.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.